Brevicidine TFA
Based on 1 Customer Validation
Brevicidine TFA is an antimicrobial peptide with selective bactericidal activity against Gram-negative pathogens. Brevicidine TFA disrupts bacterial morphology by binding to lipopolysaccharide (LPS) on the bacterial cell membrane to form pores. Brevicidine TFA causes dissipation of intracellular proton motive force, outer membrane damage, inhibition of ATP biosynthesis and reactive oxygen species accumulation in bacterial cells. As a sensitizer, Brevicidine TFA exerts synergistic activity when combined with a variety of conventional antibiotics.
For research use only. We do not sell to patients.
- Purity: 97.81%
- Formula: C74H106N18O17·xC2HF3O2
- Molecular Weight:1519.74 (free base)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Brevicidine (0-2 μM; 20 h) TFA acts as a synergistic sensitizer. When combined with outer membrane-impermeable antibiotics (Erythromycin (HY-B0220), Azithromycin (HY-17506), Vancomycin (HY-B0671)) against Acinetobacter baumannii strains, it reduces the MIC by up to 128-fold at concentrations as low as 1 μM[1].
Brevicidine (0.125-4 μM; 25 min) TFA disrupts the outer membrane of Acinetobacter baumannii ATCC 17978 in a dose-dependent manner[1].
Brevicidine (1-4 μM; 1 h) TFA inhibits ATP synthesis and induces ROS production in Acinetobacter baumannii, and this effect is enhanced when used in combination with Erythromycin[1].
Brevicidine (1-16 mg/L; 20 h) TFA selectively inhibits Gram-negative pathogenic bacteria with an MIC range of 1-16 mg/L, and shows no activity against Gram-positive pathogenic bacteria[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male)[1]
-
Dosage:5 mg/kg (monotherapy); 5 mg/kg (combined with 5 mg/kg Erythromycin)
-
Administration:i.v.; single dose
-
Result:Reduced the death rate of A. baumannii-infected mice from 80% to 60%; significantly reduced bacterial load in the liver and spleen.
Achieved 100% survival when combined with 5 mg/kg Erythromycin; showed greater reduction in bacterial loads across organs when combined with Erythromycin compared to monotherapy.
Chemical Information
-
Appearance Solid
-
Molecular Weight 1519.74 (free base)
-
Formula C74H106N18O17·xC2HF3O2
-
Color White to off-white
-
Sequence
4-Methylhexanoyl-{d-Asn}-{d-Tyr}-{d-Trp}-{d-Orn}-{Orn}-Gly-{d-Orn}-Trp-Thr-Ile-Gly-Ser (Lactone: Thr9-Ser12)
-
Sequence Shortening
4-Methylhexanoyl-{d-Asn}-{d-Tyr}-{d-Trp}-{d-Orn}-{Orn}-G-{d-Orn}-WTIGS (Lactone: Thr9-Ser12)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H2O : ≥ 50 mg/mL
* "≥" means soluble, but saturation unknown.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Brevicidine TFA Related Classifications
HY-P10519A Related Classifications
Powered by Bioz